-
Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)
(PAR-20-309)
National Institute on Aging
Application Receipt Date(s): Standard dates apply.
The first standard due date for this FOA is February 5, 2021.
-
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
(PAR-21-068)
National Institute on Aging
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Cancer Institute
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
-
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
(PAR-21-069)
National Institute on Aging
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Cancer Institute
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Not Applicable
-
NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)
(PAR-21-084)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): Standard dates apply.
The first standard due date for this FOA is February 16, 2021
-
Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
(RFA-CA-21-001)
National Cancer Institute
National Human Genome Research Institute
Application Receipt Date(s): March 10, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
(RFA-CA-21-007)
National Cancer Institute
Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021
No late applications will be accepted for this Funding Opportunity Announcement.
-
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
(RFA-CA-21-008)
National Cancer Institute
Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021
No late applications will be accepted for this Funding Opportunity Announcement.
-
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trial Optional)
(RFA-CA-21-009)
National Cancer Institute
Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on
No late applications will be accepted for this Funding Opportunity Announcement.
-
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
(RFA-CA-21-010)
National Cancer Institute
Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
No late applications will be accepted for this Funding Opportunity Announcement..
-
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
(RFA-CA-21-011)
National Cancer Institute
Application Receipt Date(s): February 22, 2021; May 27, 2021; Sept 29, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
No late applications will be accepted for this Funding Opportunity Announcement.
-
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
(RFA-CA-21-012)
National Cancer Institute
Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
No late applications will be accepted for this Funding Opportunity Announcement
-
GenitoUrinary Development Molecular Anatomy Project (GUDMAP) - Atlas Projects (U01 Clinical Trial Not Allowed)
(RFA-DK-20-013)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): February 18, 2021
-
Reconfiguration of GenitoUrinary Development Molecular Anatomy Project (GUDMAP) /(Re)Building A Kidney (RBK) Data Hub (U24 Clinical Trial Not Allowed)
(RFA-DK-20-014)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): February 18, 2021
-
Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)
(RFA-NS-21-004)
National Institute of Neurological Disorders and Stroke
National Institute on Aging
Application Receipt Date(s): March 9, 2021
No late applications will be accepted for this Funding Opportunity Announcement.
-
Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed)
(RFA-NS-21-005)
National Institute of Neurological Disorders and Stroke
National Institute on Aging
Application Receipt Date(s): March 9, 2021
No late applications will be accepted for this Funding Opportunity Announcement